Superworth

Sunshine Biopharma price to sales ratio SBFM

Market value divided by revenue over the last twelve months, since 2015.

Today, Oct 23, 2026
0.0×
8-year median
0.5×
Against its 8-year history
0th
percentile: 0 is its lowest day, 100 its highest
8-year range
0.0× to 195×
Peer median
0.0×

Sunshine Biopharma's price to sales ratio is 0.0× as of Oct 23, 2026.

That is below its 8-year median of 0.5×, lower than on 100% of days in the last 8 years.

Over that time it ranged from 0.0× in Jul 2026 to 195× in Apr 2021.

The median for 10 large drugmakers of a similar size is 0.0×.

Price to sales ratio over time

The dashed line is the 8-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.0×0.0×0.2×
20250.2×0.1×0.3×
20240.2×0.0×0.5×
20230.3×0.3×52.5×
202229.4×26.0×188×
202144.0×25.6×195×
202024.2×0.1×57.7×
20190.3×0.1×1.2×
20181.2×0.6×17.5×
2017n/m a value too high to mean anything
2016147×147×171×
201558.4×58.4×199×

Against its peers

Companies in Drug Manufacturers - General nearest Sunshine Biopharma's size, closest first, today.

CompanyPrice to sales ratio
SBFMSunshine Biopharma0.0×
DCOYDecoy Therapeuticsn/m
JAGXJaguar Health0.0×
LABTLakewood-Amedex Biotherapeuticsn/m
NXTSNexentis Technologiesn/m
VBIOValion Bion/m
ARTLArtelo Biosciencesn/m
LNAILunai Bioworksn/m
GNPXGenprexn/m
GOVXGeoVax Labsn/a
ONCOOnconetixn/m
Peer median0.0×

Where Sunshine Biopharma ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Sunshine Biopharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.